Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (HK:8329)
:8329
Want to see HK:8329 full AI Analyst Report?
8329 Stock Chart & Stats
HK$0.16
>-HK$0.01(-0.63%)
At close: 4:00 PM EST
HK$0.16
>-HK$0.01(-0.63%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.20
Previous CloseN/A
Volume90.00K
Average Volume (3M)330.65K
Market Cap
HK$164.44M
Enterprise ValueHK$37.36M
Total Cash (Recent Filing)HK$209.45M
Total Debt (Recent Filing)HK$73.02M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.51%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding426,000,000
10 Day Avg. Volume371,000
30 Day Avg. Volume330,653
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetConsistently low debt-to-equity (~0.10–0.13) gives durable financial flexibility, lowering refinancing risk and enabling the company to fund operations, R&D or acquisitions without heavy reliance on external credit. This conservatism supports stability through industry cycles.
Improved Cash Generation In 2025A material swing to strong operating and free cash flow in 2025 indicates improved cash conversion and working-capital management, enabling internal funding of capex, dividends or debt reduction. Durable cash generation reduces dependence on equity or debt raises over the medium term.
Modest Dividend Yield Supporting ReturnsA ~4.3% dividend yield provides a recurring shareholder return that can anchor investor expectations. Combined with conservative leverage and improved 2025 FCF, the payout appears more sustainable than if cash generation were weak, supporting long-term investor confidence.
Bears Say
Profitability Deterioration / Net LossMaterial margin compression and a shift to a net loss erode retained earnings and reduce the firm's ability to self-finance growth or absorb cost shocks. Persistently lower margins weaken pricing power and make long-term profitability recovery more difficult absent structural change.
Top-line Weakness / Revenue DeclineA multi-year trend of flat-to-declining revenue limits operating leverage and constrains scale economies. Sustained top-line weakness pressures margins and cash flow, making investments in R&D, commercialization or market share gains harder to fund internally over the medium term.
Eroding Equity And Volatile Cash Flow HistoryDeclining equity and negative ROE reduce the capital buffer to absorb losses and constrain reinvestment. Historical cash-flow volatility lowers confidence in sustaining the 2025 cash improvement, increasing risk that funding support will be needed during adverse periods.
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.20 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$164.44M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Aug 07, 2026 which is in 53 days.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of 3.51%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.21%
12-Months-Change
Fundamentals
Return on Equity
-5.44%
Trailing 12-Months
Asset Growth
-20.91%
Trailing 12-Months
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Essex Bio-Technology
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
Ab&B Bio-Tech CO., LTD. JS Class H
―